Anixa Biosciences wins first South Korea patent for breast cancer vaccine through 2040

Anixa Biosciences, Inc. - Common Stock

Anixa Biosciences, Inc. - Common Stock

ANIX

0.00
  • Anixa Biosciences won a South Korean composition-of-matter patent covering its breast cancer vaccine technology, extending protection through 2040.
  • The patent, exclusively licensed from Cleveland Clinic, strengthens the company’s international intellectual property position for the program.
  • Anixa cited Phase 1 results showing the vaccine was safe and well tolerated, generating immune responses in 74% of participants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA93670) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.